(4S)-3-[(2S)-2-[[(9H-Fluoren-9-ylmethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]-2,2-dimethyl-4-oxazolidinecarboxylic acid

Product Details

CAS No:878797-01-4

MF:C30H30N2O6

Appearance:white or off-white crystalline powder

Specification:98.5%

UN number:-

Package:1/5/10/25kgs/drum

Supply Capacity:公斤级

Synonyms:FMOC-PHE-SER(PSIME,MEPRO)-OH;(4S)-3-(FMOC-PHE)-2,2-DIMETHYL-OXAZOLIDINE-4-CARBOXYLIC ACID;(S)-3-[N-(9-Fluorenylmethyloxycarbonyl)-L-phenylalaninyl]-2,2-dimethyloxazolidine-4-carboxylic acid;Fmoc-Phe-Ser[Psi(Me,Me)Pro]-OH≥ 98% (HPLC);Fmoc-Phe-Ser[Ψ(Me,Me)Pro]-OH;(9H-Fluoren-9-yl)MethOxy]Carbonyl Phe-SerPsi(Me,Me)Pro-OH;(4S)-3-[(2S)-2-[[(9H-Fluoren-9-ylmethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]-2,2-dimethyl-4-oxazolidinecarboxylic acid;Fmoc-L-Phe-L-Ser[PSI(Me,Me)Pro]-OH

Product application:(4S)-3-[(2S)-2-[[(9H-Fluoren-9-ylmethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]-2,2-dimethyl-4-oxazolidinecarboxylic acid,878797-01-4,Fmoc-Phe-Ser(psiMe,Mepro)-OH,Fmoc-Phe-Ser(psi(Me,Me)pro)-OH,Pseudoproline dipeptide,Fmoc protected pseudo-proline building block,Solid phase peptide synthesis monomer,SPPS building block,Peptidomimetic intermediate,Difficult peptide sequences synthesis reagent,Peptide aggregation disruptor,Chiral amino acid derivative,Oxazolidine carboxylic acid derivative,Pharmaceutical intermediate CAS 878797-01-4,High purity peptide building block,Custom peptide synthesis reagent,API intermediate,CAS 878797-01-4 manufacturer China,Fmoc-Phe-Ser pseudoproline supplier,Suzhou Health Chemicals peptide raw material,Pseudoproline dipeptide wholesale export

 

(4S)-3-[(2S)-2-[[(9H-Fluoren-9-ylmethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]-2,2-dimethyl-4-oxazolidinecarboxylic acid serves as an indispensable pseudoproline dipeptide building block extensively utilized across the therapeutic peptide manufacturing, biopharmaceutical engineering, and modern chemical biology sectors. Specially engineered for Fmoc-based solid-phase peptide synthesis (SPPS), its central function is to prevent and disrupt peptide chain self-aggregation, gelation, and beta-sheet secondary structure formation during synthesis by temporarily introducing a conformationally constrained, proline-like cis-amide bond into the growing peptide backbone; this dramatic structural kink remarkably enhances the solvation, reaction kinetics, and coupling efficiency of long, difficult, and highly hydrophobic peptide sequences. In the pharmaceutical development of complex peptide therapeutics, it is widely utilized for the high-yield production of GLP-1 analogues, antimicrobial peptides, targeted oncology therapeutics, viral fusion inhibitors, and peptide-drug conjugates (PDCs). Upon standard trifluoroacetic acid (TFA) global cleavage, the oxazolidine ring seamlessly and quantitatively regenerates the native phenylalanyl-serine dipeptide linkage without generating side reactions, thereby significantly streamlining downstream purification and maximizing overall process efficiency.